About CureVac
CureVac is a company based in Tubingen (Germany) founded in 2000 by Florian Von Der Mulbe was acquired by BioNTech in June 2025. CureVac has raised $975.35 million across 15 funding rounds from investors including BioNTech, Gates Foundation and Baillie Gifford. The company has 983 employees as of December 31, 2024. CureVac has completed 1 acquisition, including Frame Therapeutics. CureVac offers products and services including mRNA Technology Platform and mRNA COVID-19 Vaccine. CureVac operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Tubingen, Germany
- Employees 983 as on 31 Dec, 2024
- Founders Florian Von Der Mulbe
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Curevac N.V.
-
Annual Revenue
$578.9 M (USD)896.07as on Dec 31, 2024
-
Net Profit
$175.44 M (USD)162.37as on Dec 31, 2024
-
EBITDA
$243.15 M (USD)188.28as on Dec 31, 2024
-
Total Equity Funding
$975.35 M (USD)
in 15 rounds
-
Latest Funding Round
$299 M (USD), Grant
Sep 15, 2020
-
Investors
BioNTech
& 14 more
-
Employee Count
983
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
BioNTech
(Jun 12, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CureVac
CureVac is a publicly listed company on the NASDAQ with ticker symbol CVAC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CureVac
CureVac offers a comprehensive portfolio of products and services, including mRNA Technology Platform and mRNA COVID-19 Vaccine.
Platform for developing mRNA-based medicines and vaccines.
Program focused on mRNA vaccines for COVID-19 prevention.
People of CureVac
Unlock access to complete
Unlock access to complete
Funding Insights of CureVac
CureVac has successfully raised a total of $975.35M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $299 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CureVac
CureVac has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Gates Foundation and Baillie Gifford.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Locked | Locked | Locked | |
|
Investments are made in life and health sciences companies.
|
Locked | Locked | Locked | |
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked |
Investor details for CureVac
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CureVac
CureVac has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Frame Therapeutics.
Investment portfolio details for CureVac
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunotherapies and personalized vaccines for cancer are developed.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for CureVac
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - CureVac
Detailed financials for CureVac
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curevac Comparisons
Peer comparison for CureVac
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CureVac
CureVac operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of CureVac
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curevac
Complete news archive for CureVac
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CureVac
CureVac was founded in 2000 and raised its 1st funding round 3 years after it was founded.
CureVac is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
CureVac is a funded company, having raised a total of $975.35M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CureVac is 983.
Annual revenue of CureVac is $578.9M as on Dec 31, 2024.
CureVac was established in 2000 in Tubingen, Germany, within the biotechnology sector. mRNA technologies are employed to create therapeutics targeting cancer and infectious diseases. RNAntibody platforms are used to produce functional antibodies and proteins from mRNA. Key investigational assets include CV9104, a vaccine for prostate cancer that activates immune responses, CV8102 for cutaneous melanoma, and CV9202 for non-small cell lung cancer. Focus remains on immunotherapy advancements across Europe.
CureVac's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
CureVac offers mRNA Technology Platform and mRNA COVID-19 Vaccine.
Yes, CureVac is publicly traded on NASDAQ under the ticker symbol CVAC.
CureVac has made 1 acquisition, including Frame Therapeutics.
CureVac has 15 investors. Key investors include BioNTech, Gates Foundation, Baillie Gifford, European Investment Bank, and GSK.
The ticker symbol of CureVac is CVAC on NASDAQ.